Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent
- PMID: 35746511
- PMCID: PMC9227833
- DOI: 10.3390/vaccines10060903
Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent
Abstract
Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection. The protection mechanisms of bNAbs involve the Fc domain, as well as their Fab counterpart. Here, different bNAb isotypes including IgG1, IgA1, IgA2, and IgA122 (IgA2 with the hinge of IgA1) were generated and then produced in CHO cells. Their ability to neutralize pseudovirus and primary HIV-1 isolates were measured, as well as their potential ADCC-like activity using a newly developed assay. In our work, gp41-specific IgA seems to be more efficient than IgG1 in inducing ADCC-like activity, but not in its virus neutralization effect. We show that either gp120-specific IgA or IgG1 isotypes are both efficient in neutralizing different viral strains. In contrast, gp120-specific IgG1 was a better ADCC-like inducer than IgA isotypes. These results provide new insights into the neutralization and ADCC-like activity of different bNAbs that might be taken into consideration when searching for new treatments or antibody-based vaccines.
Keywords: ADCC; HIV; broadly neutralizing antibodies; gp120; gp41; neutralization.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.Front Immunol. 2021 Sep 10;12:733958. doi: 10.3389/fimmu.2021.733958. eCollection 2021. Front Immunol. 2021. PMID: 34566999 Free PMC article.
-
Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.J Virol. 2017 Mar 29;91(8):e02440-16. doi: 10.1128/JVI.02440-16. Print 2017 Apr 15. J Virol. 2017. PMID: 28122982 Free PMC article.
-
Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.J Virol. 2021 Jun 10;95(13):e0021921. doi: 10.1128/JVI.00219-21. Epub 2021 Jun 10. J Virol. 2021. PMID: 33853957 Free PMC article.
-
Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.Front Immunol. 2017 Aug 24;8:1033. doi: 10.3389/fimmu.2017.01033. eCollection 2017. Front Immunol. 2017. PMID: 28883824 Free PMC article. Review.
-
Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.Curr HIV Res. 2013 Jul;11(5):378-87. doi: 10.2174/1570162x113116660059. Curr HIV Res. 2013. PMID: 24191939 Free PMC article. Review.
Cited by
-
Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.Front Immunol. 2023 Feb 2;14:1037033. doi: 10.3389/fimmu.2023.1037033. eCollection 2023. Front Immunol. 2023. PMID: 36817447 Free PMC article. Review.
-
Impaired mucosal IgA response in patients with severe COVID-19.Emerg Microbes Infect. 2024 Dec;13(1):2401940. doi: 10.1080/22221751.2024.2401940. Epub 2024 Oct 2. Emerg Microbes Infect. 2024. PMID: 39358866 Free PMC article.
-
Prior COVID-19 Immunization Does Not Cause IgA- or IgG-Dependent Enhancement of SARS-CoV-2 Infection.Vaccines (Basel). 2023 Mar 31;11(4):773. doi: 10.3390/vaccines11040773. Vaccines (Basel). 2023. PMID: 37112685 Free PMC article.
-
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.Sci Transl Med. 2023 Jul 5;15(703):eadh0004. doi: 10.1126/scitranslmed.adh0004. Epub 2023 Jul 5. Sci Transl Med. 2023. PMID: 37406137 Free PMC article. Clinical Trial.
References
-
- Fouda G.G., Eudailey J., Kunz E.L., Amos J.D., Liebl B.E., Himes J., Boakye-Agyeman F., Beck K., Michaels A.J., Cohen-Wolkowiez M., et al. Systemic Administration of an HIV-1 Broadly Neutralizing Dimeric IgA Yields Mucosal Secretory IgA and Virus Neutralization. Mucosal Immunol. 2017;10:228–237. doi: 10.1038/mi.2016.32. - DOI - PMC - PubMed
-
- Watkins J.D., Sholukh A.M., Mukhtar M.M., Siddappa N.B., Lakhashe S.K., Kim M., Reinherz E.L., Gupta S., Forthal D.N., Sattentau Q.J., et al. Anti-HIV IgA Isotypes: Differential Virion Capture and Inhibition of Transcytosis Are Linked to Prevention of Mucosal R5 SHIV Transmission. AIDS. 2013;27:F13. doi: 10.1097/QAD.0b013e328360eac6. - DOI - PMC - PubMed
-
- Tudor D., Yu H., Maupetit J., Drillet A.S., Bouceba T., Schwartz-Cornil I., Lopalco L., Tuffery P., Bomsel M. Isotype Modulates Epitope Specificity, Affinity, and Antiviral Activities of Anti-HIV-1 Human Broadly Neutralizing 2F5 Antibody. Proc. Natl. Acad. Sci. USA. 2012;109:12680–12685. doi: 10.1073/pnas.1200024109. - DOI - PMC - PubMed
-
- Astronomo R.D., Santra S., Ballweber-Fleming L., Westerberg K.G., Mach L., Hensley-McBain T., Sutherland L., Mildenberg B., Morton G., Yates N.L., et al. Neutralization Takes Precedence Over IgG or IgA Isotype-Related Functions in Mucosal HIV-1 Antibody-Mediated Protection. EBioMedicine. 2016;14:97–111. doi: 10.1016/j.ebiom.2016.11.024. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous